Lapatinib, an FDA-approved tyrosine kinase inhibitor, treats HER2+ advanced/metastatic breast cancer. This study comprehensively analyzed its adverse reaction profile using FDA Adverse Event Reporting
ADE = adverse drug event; CI = confidence interval. aAs one person could have multiple ADEs, the combined prevalence is lower than the sum of the prevalences of the ADE categories. bSelf-reported use
